This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Seek expert advice.

The aim of treatment should be symptomatic control and a growth hormone concentration of less than 5 mU/l.

  • if cause of acromegaly is a microadenoma then:
    • treatment of choice is transsphenoidal surgical exploration
    • further treatment:
      • if there is symptomatic improvement, insulin-like growth factor is normal, and growth hormone concentration is less than 5 mU/l then no further treatment is indicated
      • if the above conditions are not satisfied then consider external beam radiation. Also drug treatment (bromocriptine or octreotide) can be administered and withdrawn at yearly intervals in order to assess the effects of radiotherapy on growth hormone secretion

  • elderly patients with acromegaly
    • if patient is elderly and surgery is contraindicated then these patients seem to be more susceptible to the effects of octreotide than younger patients

  • patients with macroadenomas (> 1 cm in diameter)
    • transsphenoidal surgery is the treatment of choice
    • other measures such as external beam radiotherapy and drug treatment may also be indicated in order to get growth hormone levels below 5 mU/l

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.